Ishita Drugs & Industries is currently trading at Rs. 65.95, up by 1.20 points or 1.85% from its previous closing of Rs. 64.75 on the BSE.
The scrip opened at Rs. 66.20 and has touched a high and low of Rs. 74.90 and Rs. 65.35 respectively. So far 1123 shares were traded on the counter.
The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 79.55 on 05-May-2022 and a 52 week low of Rs. 34.00 on 23-Nov-2021.
Last one week high and low of the scrip stood at Rs. 75.50 and Rs. 50.20 respectively. The current market cap of the company is Rs. 19.54 crore.
The promoters holding in the company stood at 49.32%, while Non-Institutions held 50.68%.
Ishita Drugs & Industries has received an Environmental Clearance from the State Level Environment Impact Assessment Authority (SEIAA), Gujarat, for manufacturing additional products under the category 'Synthetic Organic Chemicals (API and its intermediates)' at its manufacturing unit situated at Sanand Viramgam Highway, Vasna-Iyava, Taluka Sanand, District Ahmedabad, Gujarat.
Ishita Drugs & Industries is engaged in the manufacture of various active pharma ingredients (bulk actives and their salts), bulk drug intermediates, excipients and fine chemicals. It has a state-of-art manufacturing facility, in terms of chemical synthesis, quality control and environmental safety.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.70 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1229.60 |
| Zydus Lifesciences | 915.45 |
| Lupin | 2332.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: